Increased susceptibility to erythrocyte C5b-9 deposition and complement- mediated lysis in chronic renal failure

Kidney International

Volumn 55, Issue 2, 1999, Pages 659-666

  Himmelfarb, Jonathan ^a,b,c   McMonagle, Ellen ^a,b   Holbrook, Diane ^a,b   Hakim, Raymond ^a,b  

^a Maine Medical Center Research Institute   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c MAINE MEDICAL CENTER   (United States)

Author keywords

Anemia; Complement mediated erythrocyte injury; Dialysis; Red blood cells; Uremia

Indexed keywords

ADULT; ARTICLE; CELL DAMAGE; CELL SURVIVAL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; HEMOLYSIS; HUMAN; MALE; PRIORITY JOURNAL; UREMIA;

EID: 0032962385     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00277.x     Document Type: Article

References (41)

1. 1. HIMMELFARB J: Hematologic manifestations of renal failure, in NKF Primer on Kidney Diseases, edited by Greenberg A, San Diego, Academic Press, 1997, p 465
2. 2. HAKIM RM, LAZARUS JM: Biochemical parameters in chronic renal failure. Am J Kidney Dis 11:238-247, 1988
3. 3. ESCHBACH J: The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35:134-148, 1989
4. 4. STIVELMAN JC: Resistance to recombinant human erythropoietin therapy: A real clinical entity? Semin Nephrol 9:8-11, 1989
5. 5. NISSENSON AR: Hyporesponsiveness to erythropoietin: Overview. Perit Dial Int 16:417-420, 1996
6. 6. DRUEKE TB: RHuEPO hyporesponsiveness: Who and why? Nephrol Dial Transplant 10:62-68, 1995
7. 7. CHU P, CADELY M, BELLINGHAM A: Red cell metabolism in renal failure: The effect of dialysis. Clin Lab Haematol 7:1-5, 1985
8. 8. ESCHBACH JW, FUNK D, ADAMSON JW, KUHN K, SCRIBNER BH, FINCH CA: Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med 276:653-658, 1976
9. 9. JACOB H, EAGON J, YAWATA Y: Shortened red blood cell survival in uremic patients: Beneficial and deleterious effects of dialysis. Kidney Int 89:S139-S143, 1985
10. 10. HUGHES RT, COTES PM, PIPPARD MJ, STEVENS JM, OLIVER DO, WINEARLS CG, ROYSTON JP: Subcutaneous administration of recombinant human erythropoietin to subjects on continuous ambulatory peritoneal dialysis. Br J Haematol 75:268-273, 1990
11. 11. LIM VS, KIRCHNER PT, FANGMAN J, RICHMOND J, DE GOWIN RL: The safety and efficacy maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency. Am J Kidney Dis 14:496-506, 1989
12. 12. SALTISSI D, CARTER G: Association of secondary hyperparathyroidism with red cell survival in chronic haemodialysis patients. Clin Sci 68:29-33, 1985
13. 13. KOCH KM, PATYNA WD, SHALDON S, WERNER E: Anemia of the regular hemodialysis patient and its treatment. Nephron 12:405-419, 1977
14. 14. ESCHBACH JW, KORN D, FINCH CA: C cyanate as a tag for red cell survival in normal and uremic man. J Lab Clin Med 89:823-828, 1977
15. 15. VILJOEN M, DE OLIVEIRA A, MILNE F: Physical properties of red blood cells in chronic renal failure. Nephron 59:271-278, 1991
16. 16. LANGSDORF L, ZYDNEY A: Effect of uremia on the membrane transport characteristics of red blood cells. Blood 81:820-827, 1993
17. 17. PASCUAL M, STEIGER G, ESTREICHER J, MACON K, VOLANAKIS JE, SCHIFFERLI JA: Metabolism of complement factor D in renal failure. Kidney Int 34:529-536, 1988
18. 18. VOLANAKIS JE, BARNUM SR, GIDDENS M, GALLA JH: Renal filtration and catabolism of complement protein D. N Engl J Med 312:395-399, 1985
19. 19. CHEUNG AK: Biocompatibility of dialysis membranes. J Am Soc Nephrol 1:150-161, 1990
20. 20. HAKIM RM: Editorial review: Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 44:484-494, 1993
21. 21. PODACK ER: Assembly and structure of the membrane attack (MAC) of complement, in Cytologie Lymphocytes and Complement Effectors of the Immune System, edited by PODACK ER, Boca Raton, FL, CRC Press, 1988, p 173
22. 22. DEPPISCH R, SCHMIDT V, BOMMER J, HANSCH G, RITZ E, RAUTERBERG E: Fluid phase generation of terminal complement complex as a novel index of biocompatiblity. Kidney Int 37:696-706, 1990
23. 23. PERTOSA G, TARANTINO EA, GESUALDO L, MONTINARO V, SCHENA FP: C5b-9 generation and cytokine production in hemodialyzed patients. Kidney Int 41(Suppl):S221-S225, 1993
24. 24. HAUSER A, DERFLER K, STOCKENHUBER F, JANATA O, BALCKE P: Generation of the membrane attack complex during haemodialysis: Impact of classical and alternative pathway components. Clin Sci 79:471-476, 1990
25. 25. SCHAEFER R, RAUTERBERG E, DEPPISCH R, VEINKEN J: Assembly of terminal SC5b-9 complement complexes: A new index of blood-membrane interaction. Miner Electrolyte Metab 16:73-76, 1990
26. 26. MORGAN BP, DANKERT JR, ESSER AF: Recovery of human neutrophils from complement attach: Removal of the membrane attack complex by endocytosis and exocytosis. J Immunol 138:246-253, 1987
27. 27. CAMBELL AK, MORGAN BP: Monoclonal antibodies demonstrate protection of polymorphonuclear leukocytes against complement attack. Nature 317:164-166, 1985
28. 28. CARNEY DF, KOSKI CL, SHIN ML: Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: The rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9. J Immunol 134:1804-1809, 1985
29. 29. IIDA K, WHITLOW M, NUSSENZWEIG V: Membrane vesiculation protects erythrocytes from destruction by complement. J Immunol 147:2638-2642, 1991
30. 30. MAYER MM: Mechanism of cytolysis by complement. Proc Natl Acad Sci USA 69:2954-2958, 1972
31. 31. OKADA N, HARADA R, JUJITA T, OKADA H: A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol 1:205-208, 1989
32. 32. NICHOLSON-WELLER A, BURGE J, FEARON DT, WELLER PF, AUSTEN KF: Isolation of human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertase of the complement system. J Immunol 129:184-189, 1962
33. 33. HOLGUIN MH, FREDRICK LR, BERNSHAW NJ, WILCOX LA, PARKER CJ: Isolation and characterization of a membrane protein form normal human erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 84:7-17, 1989
34. 34. DAVIES A, SIMMONS DL, HALE G, HARRISON RA, TIGH H, LACHMANN PJ, WALDMANN H: CD59, a Ly-6-like protein expressed in human lymphoid cells, regulates the actions of the complement membrane attack complex on homologous cells. J Exp Med 170:637-654, 1989
35. 35. SALAMA A, HUGO F, HEINRICH D, HOGE R, MULLER R, KIETEL V, MUELLER-ECKHARDT C, BHAKDI S: Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass. N Engl J Med 318:408-414, 1988
36. 36. HALPERIN JA, TARATUSKA A, RYNKIEWICZ M, NICHOLSON-WELLER A: Transient changes in erythrocyte membrane permeability are induced by sublytic amounts of the complement membrane attack complex (C5b-9). Blood 81:200-205, 1993
37. 37. HALPERIN JA, NICHOLSON-WELLER A, BRUGNARA C, TOSTESON DC: Complement induces a transient increase in membrane permeability in unlysed erythrocytes. J Clin Invest 82:594-600, 1988
38. 38. CHEUNG AK, PARKER CJ, WILCOX LA, JANATOVA J: Activation of complement by hemodialysis membranes: Polyacrylonitrile binds more C3a than cuprophan. Kidney Int 37:1055-1059, 1990
39. 39. TOMLINSON S, WHITLOW MB, NUSSENZWEIG V: A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes C5b-9. J Immunol 152:1927-1934, 1994
40. 40. ROSENMUND A, BINSWANGER U, STRAUB P: Oxidative injury to erythrocytes, cell rigidity and splenic hemolysis in hemodialyzed uremic patients. Ann Intern Med 82:460-465, 1975
41. 41. ZACHEE P, FERRANTE A, DAELEMANS R, COOLEN L, GOOSSENS W, LINS RL, COUTTNEY M, DE BROE ME, BOOGAERTS MA: Oxidative injury to erythrocytes, cell rigidity and splenic hemolysis in hemodialyzed patients before and during erythropoietin treatment. Nephron 65:288-293, 1993